This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point. Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 ... is $20.01 and its 200 day moving average is $18.50. The stock has a market capitalization of $18.79 billion, a PE ratio ...

Thank you for dialing in for the call. Really excited to talk to you today about the 2024 performance of Teva and the lookout for 2025. So as usual, I'm going to go back to the strategy ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel ...